Email us for help
Loading...
Premium support
Log Out
Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.
What is Laqunimod? Laquinimod is an experimental drug from TEVA Pharmaceuticals that has already been tested in previous clinical trials in several diseases including Multiple Sclerosis (MS). This drug is thought to affect (or modulate) immune activity by shifting an injurious inflammatory situation to one that is more protective and anti-inflammatory. There is also evidence from various clinical trials that laquinimod may delay progression of disability in MS, and that it reduces brain atrophy as measured by MRI brain scans. By reducing brain atrophy, this drug may have neuroprotective effects [Varrin-Doyer 2014]. This drug can trigger protective neuron factors like BDNF (as measured in blood of MS clinical trial participants) that supports the health of neurons.
We will be talking about LEGATO-HD clinical research trial that will test the safety of Laquinimod.